Ex-Goldman Banker Uses Big Data to Beat Biotech’s Long Odds
- Simone Song bets on bespoke analysis to pick biotech winners
- Quantifying risk is key as industry struggles with a downturn
This article is for subscribers only.
Simone Song isn’t afraid of the numbers.
As the former head of health banking for China at Goldman Sachs Group Inc., she was well aware of the staggering odds biotechnology companies face when she started her own venture fund in 2015.